Good morning, and welcome to Sharecare's third quarter 2021 earnings conference call and webcast. All participants will be in a listening mode. After today's presentation, there will be an opportunity to ask questions. Leading today's call are Mr. Jeff Arnold, Chairman and CEO, and Mr. Justin Ferrero, President and Chief Financial Officer. Before we begin, we would like to remind you that certain statements made during this call will be forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to various risks and uncertainties and reflect our current expectations based on our beliefs, assumptions, and information currently available to us. Although we believe these expectations are reasonable, we undertake no obligation to revise any statement to reflect changes that occur after this call. Descriptions of some of the factors that could cause actual results to differ materially from these forward-looking statements are discussed in more detail in our filings with the SEC, including the Risk Factors section of the prospectus for our business combination filed with the SEC on June 3, 2021. In addition, please note that the company will be discussing certain non-GAAP financial measures that we believe are important in evaluating performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliation of historical non-GAAP financial measures can be found in the presentation that is posted on the company's website. I would now like to hand the conference over to Mr. Jeff Arnold. Please go ahead. Good morning, everyone, and thank you for joining Sharecare's third quarter fiscal 2021 conference call. I'm very proud that we delivered another strong quarter of financial performance and further expanded the reach of our digital health platform to enable millions of members, employees, and consumers to consolidate and manage all their health in one place, regardless of where they are on their health journey. By partnering with leading payers, providers, life science companies, and employers, we make it easy for them to buy, implement, and engage with their populations to measurably improve their overall well-being. Now, let me provide a brief overview of our financial results for the quarter. The third quarter results reflect the momentum we are seeing in the market, exceeding our expectations. We beat our revenue and adjusted EBITDA guidance, delivering revenue growth of 32% to $105.6 million compared to the prior year period, and adjusted EBITDA of $7.9 million. The results demonstrate the continued execution of our land and expand strategy, the advancement of our business development initiatives, and the initial successful integration of our recent CareLinx acquisition. We also continued to bolster our team with key executive hires, including Jaffry Mohammed, who led UST's healthcare business and was previously with Anthem, Kevin O'Laughlin, who ran Salesforce's healthcare sector, working closely with health plans, including Anthem, and our new Head of Investor Relations, Evan Smith, joining us from Change Healthcare. Additionally, I'd like to congratulate our Chief Medical Officer, Dr. Nirav Shah, on his recent appointment to the advisory committee of the CDC director. We are continuing to build momentum, which gives us great confidence for growth and profitability for the remainder of fiscal 2021 and in fiscal 2022. Let me provide some color on our performance by channel, starting with enterprise. In the second quarter, we expanded our relationships with key enterprise clients as well as won several new clients, including Lennar and Aflac, which will begin to ramp in the fourth quarter and early next year. We also launched several government-sponsored and commercial health plans during the quarter. I would also note that we are executing well on the implementation of previously disclosed program wins, including both Centene and Humana's CarePlus, as well as with corporate clients like Nordstrom and Lockheed Martin, among many others. As a result, we continue to expand our base of lives and are on track to end the year with nearly 10 million lives on the platform. In addition, we're also seeing increased engagement in our deployed digital therapeutics, which will be a significant growth driver over the next few years as we increase penetration with current customers and expand our total market opportunity. To further support growth in this area, we launched Unwinding by Sharecare, a broad-based mental well-being app designed to help people better understand how their minds work, reduce their stress, and build healthier habits. It's based on more than a decade of research by renowned neuroscientist and addiction psychiatrist, Dr. Jed Brewer, who became Sharecare's Executive Medical Director of Behavioral Health when we acquired MindSciences in July 2020. Unwinding complements our suite of award-winning digital therapeutics that are clinically proven to help people overcome behavioral health issues, including anxiety, smoking and vaping, and emotional eating, introducing new growth opportunities in both consumer and enterprise. These proven digital therapeutics address employers' increasing demands for science-based behavioral health solutions and seamlessly integrate into a comprehensive virtual care platform by empowering people to improve and manage the interconnected aspects of their physical and mental well-being. Lastly, I'm very proud of the team given the integration of CareLinx, which is performing well against plan. With the increasing activity in home health right now, I'd like to take a minute to reinforce the competitive advantages Sharecare has realized through this acquisition. To recap on our last call, CareLinx is a leading in-home care technology platform with a nationwide network of more than 450,000 tech-enabled care providers that deliver on-demand personal care services endorsed by AARP since 2018, with more than 1.5 million Medicare Advantage members having access to their services today. CareLinx tech-enabled care providers support the functional needs of seniors and patients living with chronic conditions while helping address isolation and loneliness. Through these home visits, CareLinx's digital platform facilitates rich social determinants of health data capture, population health analytics, and real-time care coordination with remote clinical teams to administer in-home monitoring and digital care plans to close identified gaps in care, ultimately delivering over 3.3 million hours of home-based care. Today, CareLinx is being recognized at a White House event with the Elizabeth Dole Foundation for their Respite Relief program that supported over 1,600 military and veteran families amid the pandemic. In addition to CareLinx's strong performance in the quarter, we see significant opportunities as we cross-sell their capabilities to our existing customer base, as well as leverage their capabilities to drive new integrated solutions, including becoming a unique component, differentiating the payer-agnostic advocacy solution we are developing in partnership with Anthem, Sharecare Plus. By building on the scale and strength of the Sharecare platform, our advocacy solution, Sharecare Plus, will harness the power of Sharecare's industry-leading capabilities in data and artificial intelligence to drive more informed precision health decisions and improve outcomes by leveraging our existing digital capabilities from benefits navigation and risk assessment to digital therapeutics and decision support. Sharecare Plus will have all the components to deliver a comprehensive, best-in-class, flexible solution to address the needs of employers, health plans, and providers. We bring this to market working closely in partnership with Anthem, providing their customers seeking a payer-agnostic solution where we are uniquely positioned to engage with people at every step of their health journey, and more importantly, engage with them how and where they prefer to engage, whether via digital assistant or talking to a live person on the go or in the home. Now let me move on to our provider channel, which services approximately 6,000 physician practices, hospital systems, and health plans. We continue to see positive trends with strength in volumes and demand for our medical record retrieval, payment integrity, and value-based care solutions. Showing the strength and diversity of our opportunity across this channel, during the quarter, we signed contracts with leading payers and regional hospital systems for our record retrieval business, which received the highest overall performance rating in the 2021 KLAS ROI Vendors Report. We signed a new contract for our payment integrity offering with a division of one of the largest health and life reinsurance companies in the world. We launched our unified patient and provider solution suite with a regional medical center and multi-specialty physician group to Sharecare enable their clinicians, and signed contracts for value-based care offerings, which will begin in the first quarter of 2022. Moving to our consumer solutions channel, which focuses on leveraging our platform to implement targeted audience-specific messaging campaigns on behalf of pharma and life science companies, we had a very strong performance in Q3, which reflects Sharecare's ability to deliver strong results against brand goals and the power of our 108 million first-person database. The consumer solutions channel continues to build momentum, adding approximately 25 significant new brands since this time compared to prior year, with positive trends in average revenue per new brand, supported by a significant increase in the number of million-dollar-plus campaigns. The team has already built momentum for next year, selling its suite of 2022 client solutions featuring immersive content experiences and new advanced targeting capabilities, which leverage insights from Sharecare's Community Wellbeing Index. We have integrated new capabilities from our doc.ai acquisition to further efforts to decentralize clinical research and are actively marketing Smart OMIX to pharmaceutical and life sciences companies to advance relevance, equity, and data integrity in research through artificial intelligence-powered smartphone-based studies. In fact, a recent observational study conducted on behalf of global biopharmaceutical company UCB exemplified this futuristic approach to research by building objective measures of symptoms of a rare disease, achieving diverse representation among the affected population, and automating a collection of rich patient-generated data streams. Through Smart Omix, we are realizing the future of medical research today by conducting these virtual studies, which yield highly relevant real-world findings at speed and scale. With partners like UCB, we are able to maximize not only our understanding of specific conditions, but also build a complete digital journey from research to care for people everywhere. We are excited about the potential in these areas, which will further support our growth in fiscal 2022. As I've demonstrated by our results across all our channels, we have multiple avenues to drive growth, including signing new clients, cross-selling additional solutions to our current customers, expanding our digital therapeutics and value-based care offerings, and launching new products. Based on the strength of our platform and momentum to date, we remain confident we can deliver strong, recurring, organic revenue growth with additional growth opportunities as we further enhance Sharecare's capabilities through strategic acquisitions. Now, I'll turn the call over to Justin for a more detailed review of our third quarter financial performance. Justin? Thanks, Jeff, and thanks to everyone on the call for your interest in Sharecare. As Jeff indicated, we delivered another strong quarter, with both revenue and adjusted EBITDA exceeding our guidance. As evidenced by the results, we continue to gain momentum in the business, delivering strong sequential and year-over-year revenue growth and positive adjusted EBITDA, while continuing to invest heavily to support our future growth. During the quarter, we hired several key executives, as well as attracted great talent across the organization to support our growth. Digging into the quarter, our total revenue grew 32% from $80.2 million a year ago to $105.6 million, which also represents more than 7% sequential quarterly growth. This was primarily driven by increased client penetration, executing on our land and expand strategy, and new client implementations and wins across the entire platform. On an organic basis, we grew total revenue in excess of 20% compared to the third quarter of the prior year. I would also note that recently acquired CareLinx is performing in line with, if not ahead of, our initial expectations. Adjusted EBITDA for the quarter was $7.9 million, which was also ahead of previous guidance of $6 million-$7 million, and which reflects increased investments in the current period for both technology and sales force expansion. We expect the investments to support our long-term growth and drive additional operating leverage as we gain greater traction for the Sharecare digital platform with existing and new customers. I'll now turn to our guidance for the fourth quarter and full year. Our Q4 guidance for revenue is $120.3 million-$121.3 million, and adjusted EBITDA is expected to be $8 million-$9 million. The fourth quarter guidance reflects strong sequential growth as various initiatives ramp, as well as seasonality in our consumer solutions channel, which generates more than 30% of its revenue in the fourth quarter, as life science companies typically increase their spend for the end of the year. In addition, adjusted EBITDA includes the previously disclosed negative impact from CareLinx and additional investments in sales and technology, as well as the seasonal impact of certain marketing-related expenses which occur in the fourth quarter. For the full year 2021, we are reiterating our revenue guidance of $414 million-$415 million, while increasing the midpoint of our adjusted EBITDA guidance, which is now expected to be in a range of $29 million-$30 million, increasing the low end of the range from $28 million to $29 million. This reflects the strength of the third quarter and that we are essentially fully booked for the remainder of the year. Now, I'll hand it back to Jeff for some closing remarks. Thanks, Justin. As you can tell, we continue to build momentum as we move through the first nine months of the year, delivering on our financial, operational, and growth objectives. As a result of new business wins, new solution introductions, strategic acquisitions, and a strong balance sheet, we have established an extremely strong foundation and runway to support future growth and profitability. Again, I want to thank everyone on the call today for your continued interest in Sharecare. We have a significant opportunity ahead of us, and I look forward to continuing to update you on our progress. With that, we'll open the call for any questions. Operator? Thank you. To ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Our first question comes from Eric Percher with Nephron Research. Your line is open. Good morning, and thank you. A question on the number of lives on the platform, and it's good to hear you're nearing the goal of 10 million. When we look at go lives in 2021, what has the trend been in January versus April, July and October, relative to what you've seen historically and maybe what you saw in a disrupted 2020? Hey, Eric, it's Justin. Thank you for the question. You know, based on our conversations, we're really tracking exactly to what we expected this year. I think you remember we provided, at the end of last year, we ended at 8.8 million lives and provided guidance to 9.7 million. We're growing sequentially quarter-over-quarter and expect to, as Jeff alluded to in the opening, to hit our target of 9.7 million by the end of the year. All right. It sounds like there's not any real difference relative to how lives ramped in prior years. Maybe I'd ask then, you know, what is your perspective on additions from expansion of accessible lives versus penetration of the accessible lives you currently have? Well, we don't break that out, but it's again, where we focus is to make sure we hit the target and the KPI that we provided, which we are going to do. We have a lot of ways to drive growth, as you know, which is you know from bringing on new client wins to expanding with our existing customer base, which is significant, to cross-selling, and we expect all of those to contribute to our growth as we look into 2022. Maybe Justin, I might add to that. Hi, Eric, this is Jeff. You know, I think what's unique about Sharecare is, you know, we have these really large health plan clients. There's tons of opportunity to grow with those clients. I mean, we're just scratching the surface on the number of covered lives that Anthem has or Centene has. We're constantly trying to bring on members onto the platform throughout the year. At the same time, you know, we're having success in the large self-insured employer space. In the past, we've talked about wins like Delta and State Farm. I mentioned in my opening comments recent wins, like with Aflac's employees or Lennar employees. We had mentioned that we're bringing on 90 salespeople, and we announced, you know, or I mentioned in my comments, you know, Jaffry and Kevin, who have joined us, with Pam to lead that effort. But we've also brought on 24 salespeople, since we had our last call, and that's starting to ramp as well. It's this really nice kind of one-two punch of, you know, grow from within these large health plans, you know, prove that our services work for them and add more members, and at the same time, add new logos to the roster, which, you know, on the combined basis, increases our total eligible lives. Jeff, you make a great point there. It felt like for some time, most of the wins we saw were coming in the Georgia neighborhood. How far in are we on those 90 additions to actually be out there and productive? How do you think about productivity ramping? They're coming up to speed fast. As you know, this is a little bit of a sales cycle. We expect those salespeople to be contributing new logos in 2022. We're already seeing their participation in some of the logos that I mentioned, like Aflac and like Lennar. Our pipeline is way more robust this year than even it was last year. We're getting a lot more at-bats. I think, you know, our brand is more known than it was a year ago, but just the volume of RFPs that we're getting is, you know, I'd probably say 5x what it was last year. Yeah, one thing, Eric, that might have not been clear from your research report is that we laid out that 90 salespeople we were gonna hire over a period of three years. I don't know if that came across to you when we spoke earlier. We're right on track through three quarters of the year to hire, you know, north of 30 this year and right in line with the guidance of 90 over the next three years. That's helpful. Maybe last financial question. Transaction costs was the full $16.8 million in G&A. Justin, any guidance you can give us relative to stock-based comp across the expense line items? Yeah. The stock-based comp was significant as well. Really, there was three areas. The $16 million is on the transaction expenses. There was $11 million on the stock-based comp, which was all transaction-related, due to vesting of shares. That was $11 million. I think it's important to point out, we paid off all of our debt. We have a very clean balance sheet, and so you saw $12 million come out of our, you know, accrued deferred financing fees. Great. That's helpful. Last one. After 2 quarters as a public company, the CareLinx acquisition, how should we think about headwinds and tailwinds relative to 2022 and the numbers you provided back in the S-4? Well, Justin, you wanna I'll let you take that, but as far as maybe explaining CareLinx after the S-4. Yeah. You wanna do that? We reiterate our guidance there. As you know, we provided guidance around $7 million for the year. We're very confident in 2021's numbers. We grew that to $35 million for 2022. We're very confident in achieving that 70% growth year-over-year. The integration has been fantastic with CareLinx, and we see that as a fantastic transaction for our shareholders, very accretive, and it's gonna pay dividends for years to come. Yeah. We now have 250 health plans on CareLinx, which makes up 1.5 million Medicare Advantage members. Perfect. Thanks so much. Sure. Thank you. The next question comes from David Larsen with BTIG. Your line is open. Hi. Congratulations on a very good quarter. Can you talk a little bit about your relationship with Anthem and some of these other large health plans? Everybody's talking about digital-first plan designs. UnitedHealthcare talked about it, Anthem talked about it, CVS, Aetna talked about it. Can you maybe just give some color around what Sharecare's contribution is there to your clients? Thank you. Sure. Hi, David, this is Jeff. I think we play an important strategic role with our clients, and particularly, you asked about Anthem. With Anthem's Sydney, we play a significant role with our artificial intelligence services. It powers much of that platform, as well as we have other Sharecare solutions that we're driving through Sydney. In addition to that, as you know, you know, when Anthem made their $50 million investment in April into Sharecare, it was so that we could co-develop our Sharecare Plus solution, which is for multi-payer advocacy. Anthem, where they have, you know, large employers in which they're not 100% on Anthem, they're leading with the Sharecare Plus solution, as well as we're selling that solution to our other clients as well. It's helping our clients leverage all the capabilities that Sharecare has assembled over the last decade, and then becoming our own, you know, digital front door when appropriate, especially for their multi-payer clients. We see lots of growth opportunities within all of those relationships. Mm-hmm. Okay. Is UnitedHealth Group a client of CareLinx, or is there cross-sell potential there? Yes. CareLinx does have a significant relationship with UnitedHealthcare, as well as some other new payers that we didn't have on our roster in the past. We're hopeful that relationship will continue to grow for CareLinx. It has from 2021 to 2022, as well as it'll give us an opportunity to cross-sell some other Sharecare capabilities. Okay. I think that doc.ai serves a very large number of Anthem members, like through Sydney. Isn't that in like the multimillion-dollar range, like maybe the 3-10 million members? I would think that. Like, what is the rate or the price that you're charging for those lives? I'm just thinking about the PMPM upsell potential. Hey, it's Justin. Thanks for the question. We don't charge that on a PMPM basis. We charge it more as a license fee, and it's a long-term relationship with Anthem, and it's in the double-digit millions. Okay. Great. Then just my last question here is on the provider side, it sounds like you've got very good selling momentum there. Any thoughts on what impact the surge from the Delta variant had? It doesn't sound like it slowed down the medical record retrieval business. Just any thoughts or color there? Are you still, like, 95% booked? You had talked about the 4,000 sites that you could in-sell into longer term. Just any update or color there would be helpful. We are. That division's performing very well. As you saw, there's sequential growth in that business from Q1 to Q2 to Q3. We expect more in Q4. We're gonna do a record number of record retrievals this year. Our KPI there is 5 million, and we're tracking to hit that. Very pleased with the performance of the provider division. Yeah. I'd say, David. Okay What's nice about that division too is we're starting to see the cross-selling that we had hoped for. I think we had mentioned in the past, Emory Healthcare, for example, which is 20,000+ employees, will come onto the platform in January as an enterprise client. Wellstar, 20,000+ hospital employees will come onto the platform, as an enterprise client. We have got these 6,000 clients out there in which we're retrieving 5 million medical records. Our new sales force is seeing that as, like, a really rich opportunity, as often these health systems are the largest employers in their city, to come onto the Sharecare platform as enterprise clients in addition to the ROI services. That's great. What sort of traction have you seen around Health Security and vaccine-related wins? I know you've developed or are developing a vaccine passport that could be used in stadiums, restaurants, hotels. What sort of lift are you seeing there, if any? Well, I think we've positioned ourselves really well. You know, we reacted quickly to the pandemic and built a tech-enabled solution to help the world reopen. That product has been adopted in over 80 countries in the hotel business with a few thousand clients. I saw last night we just surpassed 2,000 restaurants that are Sharecare verified. We've got amazing relationships in the arena space and continue to bring on new arenas. We have a really great health path that's easy to implement, and you've seen the Biden mandate around, you know, employers with 100+ employees. We think we're really well positioned to be able to use our system as that mandate rolls out. We just made our first sale under that value proposition last week. You know, we're in conversations with big tech companies, global companies, government, so we think that this is here to stay. It's like I've said in the past, health security is like cybersecurity, and we're real well positioned to be able to deliver that to our clients and build our brand. Great. Thanks. Congrats on a good quarter. I'll hop back in the queue. Okay. Thanks, David. Thank you. As a reminder, to ask a question at this time, please press star then one. Our next question comes from Richard Close with Canaccord Genuity. Your line is open. Great. A lot of my questions have been asked and answered here, but just maybe going a little bit deeper on Sydney and Anthem. When Anthem gives an update, like in their most recent call, that you know, they have more than 50 national accounts signed up for Sydney Preferred, it represents like 900,000 commercial members. Just to be clear, you know, as they grow that, it doesn't necessarily positively impact Sharecare because you have that you know, guaranteed minimum contract with Anthem, uh, with respect to from legacy doc.ai? Well, you know, we think that we're a good strategic partner with Anthem. As they continue to deploy more and more digital solutions and make digital a more and more of a priority, which they're obviously doing, that Sharecare is gonna have a major role in that. You know, whether it's the artificial intelligence services that we'll be providing throughout their platforms through the doc.ai or other solutions that Sharecare has that can be sold through Sharecare or sold through Sydney or sold through Sharecare Plus. We're very engaged, you know, with them and what their needs are, and have a lot of capabilities across both Sydney and Sharecare Plus that we think will be valuable to their members as well as help them win new business as well. Yeah. No, I understand that. I'm just trying to, you know, gauge, like should we be looking at like Anthem as a read-through of, you know, potential upside to you guys on a quarterly basis? You know, if we track the number of accounts that they're reporting or the number of members, you know, because you have that minimum guarantee contract over a period of time, it doesn't necessarily mean it's incremental to you guys until you potentially meet that minimum, right? Well, they use that minimum commitment for us to provide AI to their platform. Mm-hmm. It's not live dependent. It's embedded into the core platform. Mm-hmm. We're included often in many of those RFPs, and so we've been, you know, writing Sharecare services into many of those Anthem RFPs as they've gone to market, especially with national accounts talking about Sharecare+. Okay. That's where we expect the lift. Okay. That's helpful. Thank you. With respect to the competitive market, obviously there's a lot of talk on navigation and advocacy and all that. How are you guys thinking about the, you know, competitive landscape? Obviously, you have a great partner in Anthem and a, you know, foot in the door there, with that partnership. Overall, how are you thinking about the competitive environment on, you know, call it navigation advocacy? I think we think of it holistically, and that we're really well positioned because we were a platform before platforms were cool. We think about these four pillars that we've assembled at Sharecare that are valuable to Anthem, but they're also valuable to our other Blues clients, to our Medicaid partners, our Medicare Advantage partners, our self-insured employers. It's, you know, how do you do digital navigation? Think of that like RealAge plus doc.ai to predict cost of care and outcomes. Then how do we have a really strong offering again across three other pillars of intervention? Mm-hmm. The second pillar and the first of intervention is digital therapeutics. Because we have such high engagement, we get higher utilization of the right digital therapeutic at the right time and solve a big pain point for our clients of trying to aggregate all these point solutions. The third is this advocacy, you know, where we're building out this Sharecare+, and so we'll kind of be this one-stop shop across multi-payer opportunities. Lastly, this last mile of healthcare, you know, being able to have 450,000 caregivers that we can deploy across the country, and we're starting to really think of those 450,000 tech-enabled caregivers as advocates themselves. When you take that we've had 50 million people take our HRA and engage in our content, we've got the most robust digital therapeutic marketplace, we've got a spot-on advocacy solution that we're developing hand in hand with one of the largest payers, so we're getting it right the first time, and then we've got this last mile covered, all on one platform where the data is interoperable. It's what we believe to be user-friendly. And we're seeing that. You know, we're getting wins across the board. It's not just Anthem, you know. We're super excited. Then you take into account that we also have a $100 million provider business and a big consumer business, and those three all work together in one ecosystem on one platform. We believe that we're this category of one company that we talked about in our roadshow. Great. Helpful there. Then on the consumer side, maybe to dive in there a little bit. Obviously we're coming up on 2022. Justin, you mentioned fourth quarter is usually the strongest quarter there. I think you said 30% of the year comes in the fourth quarter. You know, based on your discussions with clients, you know, how are they thinking about, you know, the shift from, you know, legacy marketing and, you know, channels versus the digital? Any thoughts regarding, you know. I know it's early for 2022 guidance and all that, but, any thoughts in terms of just like how those budgets, your customers' budgets are looking towards, you know, mix shift towards digital? Yeah. Hi, this is Jeff. Our consumer division is really strong. We have a tremendous leader, a great team. We have a lot of experience in this space, you know, going all the way back to WebMD in the, you know, late 1990s. We've been working in digital health with pharma for a long time. This was a big year for pharma, kind of a bounce back from COVID. I think what pharma and life science companies appreciate about Sharecare is our first-party database. You know, we have 108 million people on our first-party database. I think we have, like 70 million emails, as an example. They really appreciate our high quality content, our ability to produce high quality content. I think we have a library of over 40,000 videos, for example, and be able to perform for them because of that quality content and the quality of our database, so they keep coming back to us for new campaigns. We expect this division is gonna continue to grow for us, and it underwrites all the content that we produce for enterprise, which really differentiates us from our peer set, just the volume of content that we can use to personalize the experience for our users. I'd also like to note that we're real excited about the capability that we picked up with doc.ai, called Smart Omix, which is their decentralized clinical trial product. We put out a press release last week about our first client on there, UCB. If you take all the relationships that we have in pharma and life sciences that we've earned over the last, you know, two decades, you know, performing against their campaigns, and now we bring them this decentralized clinical trial product that's state-of-the-art and introduce them to doc.ai, we think that this has massive potential, you know, for us long term. It's been really well received, you know, by our clients and we think it's gonna be a big contributor. You'll start to see it next year, but in 2023, we think it's gonna really take off. Okay. A final question on consumer. You know, there's been a lot of noise on the marketing and advertising side with changes in privacy, you know, cookies, whatnot, Apple's changes. You know, does anything like that impact you guys, Sharecare, you know- Yeah With respect to, you know, that situation? It's a great question, and it's a great opportunity for Sharecare, because of that first-party database that I referenced. Cookies could go away tomorrow. It's irrelevant to how we deliver our campaigns. Okay, great. If I could slip a couple in on the provider side, just, can you talk a little bit more about, you know, what you're seeing on payment integrity and, you know, value-based care, you know, efforts on those two fronts would be helpful. Sure. Yeah. You know, obviously we're highly focused on enterprise, but you know, we see our provider unit as a great growth opportunity as well. How do we take this $100 million unit and grow it? One is we have 6,000, you know, clients, and we can cross-sell enterprise and other things to them. We've remained focused on this idea of a Sharecare-enabled clinician. The thinking there is, as value-based care you know, takes off, that the providers and health systems are gonna need the same types of platforms that the payers are buying from us to take on risk. We have this obviously, and we've repackaged it for health systems. Then we made two acquisitions to complement that strategy. One was WhiteHatAI, which is on the payment integrity side. We're starting to see some real traction there as well. You know, basically being able to identify abnormalities and then be able to confirm it within the Sharecare platform. I'll let Justin, you know, talk to the revenue there, and then, maybe I'll come back to the value-based. Richard, hey, Justin. You know, as we talked about, we expected value-based care, payment integrity to be a contributor in the second half of 2021, and that's happened. Which Jeff outlined in his opening remarks is, you know, we're executing on this large value-based contract and also a payment integrity contract. We're set up now not only to have nice contribution from them in Q4, but also good momentum as we go into 2022. On the value-based care side, you know, I mentioned we'll be launching that with customers in Q1 of 2022. That is resonating with our clients. They're like, "Bring me the same platform that the payers have as we go into value-based care." Great. Thank you very much. Congratulations. Thank you. Our next comes from Ben Sharland with Cantor Fitzgerald. Your line is open. Hey, guys. Thanks for taking my question. I just wanted to follow up on the consumer segment. It seems like you guys have a very unique signal for advertisers relative to some of the other media platforms. Can you help me frame the opportunity? You disclosed 108 million first-party users. Is there any way you can provide a bit of color on how many of these users are actively engaged with the platform? You know, at 108 million users, that would suggest, you know, ARPU of roughly $0.65 in 2021, which to me says, you know, you're in the very early stages of monetization here. Moving forward, is the major driver of monetization expansion increasing the engagement from these users or maybe growing the advertiser base? Any color there would be helpful. Thanks. Yeah. I think it's renewing brands, which we have a high renewal rate. It's adding new brands, you know, to the roster, often from existing, you know, clients that are launching new brands. But I think we have enough capacity to fulfill these campaigns, and it's coming up with new products, you know, which we've done a really good job of, you know, of continuing to kinda innovate in that space. Like, we have a product called Sharecare Reality Lab, where we build these really immersive kind of the Google Maps of the human body that has been really well adopted, and I mentioned the Smart Omix product. But I think we've got the database. The database continues to grow. We got excellent leadership, a great team, lots of history in the space. I think we won 17 awards, you know, recently, for the quality of our content and our ability to innovate and deliver for our clients. It's just a matter of keeping what we've got, bringing on new logos, adding more brands, and continuing to introduce new products. Okay, great. Thanks for the color, guys. Sure. Thank you. Our next question is a follow-up from David Larsen with BTIG. Your line is open. Hi. Can you talk a little bit more about the virtual clinical trial activity that you have going on? Maybe describe in detail what you're doing, please. Are you actually helping to conduct the clinical trial and recruit patients into those trials based on the data that you have on those members? Thanks. This is one of doc.ai's kind of premise when we bought them was this idea of how to go from research to care, believing that the smartphone could be an amazing data collection platform within itself. You know, how could you build a platform that could collect data from the smartphone that had the artificial intelligence built in that could start to make predictions, you know, faster that could help researchers? This was, I mean, this is kind of what one of the core foundations of doc.ai, this research to care using AI, research for researchers. We've taken that product that they've continued to nurture, and we've introduced that to our consumer group and said, "Hey, you guys have all these relationships with all these pharma brands. We have all these users, and we've got this great technology, and how could we create our version of Operation Warp Speed? The same way the vaccine came to life, you know, in a year, you know, how can we use our technology and our users, and our relationships so that we can accelerate discovery? I think we're really well positioned, you know, to be able to do that. You know, we announced it last week. We're on stage in Boston this week with UCB, talking about the results that we've seen. We're seeing a lot of demand for conversations and business development opportunities that we, you know, think give us a great outlook for the future of decentralized clinical trials and the role that Sharecare can play in it. Great. Thanks very much. Thanks, David. Our next follow-up comes from Eric Percher with Nephron Research. Your line is open. Thank you. I wanted to follow up a bit on your digital therapeutic commentary. It's good to hear about the new program. What tools are getting the most interest? Particularly for Unwinding, where do you think there's pent-up demand? I think for Unwinding just the whole behavioral health space is on fire within our clients. We've taken a kind of an interesting angle on this. One is, when we acquired MindSciences during the pandemic, what we liked about MindSciences is it was evidence-based. They had done $13 million in research with NIH, and Yale, and Brown, and others, and it was all based on mindfulness. You know, what relationships do you have with food, you know, so they could help you lose weight? Or what relationship, you know, do you have with, you know, smoking and other things? What we found in our research is that, you know, financial stress is a really big issue. I've said in the past, like financial stress is the next diabetes that, you know, people are worried about, you know, losing their jobs and retirement and all these different things. We went back to the team at MindSciences, and we said, "Look, you've got this amazing evidence-based mindfulness approach. All the surveys and research that we're seeing is that people are under tremendous financial stress. You know, how can we build a solution that we could bring to our enterprise clients and consumers that could help with that?" Internally, we developed Unwinding off of that research. Our salespeople are actively selling that for 2022. We're going back to all our clients right now and trying to upsell that so that they can make it available to their members in 2022. It's really resonating, the approach of mindfulness as well as the recognizing the issue of financial stress. The opportunity is to sell it into our current base because it's like turning on Wi-Fi. It's integrated already into the platform. We just hit a switch, and it's active for our clients, and it's just getting it on contract with them, then getting those members enrolled into the platform. We see that as a huge opportunity. Diabetes prevention is always huge. You know, there's 88 million people that are pre-diabetic. You know, we have a solution for that, and that continues to grow. All your staples people are always interested in is, you know, trying to lose weight and stop smoking, et cetera. Yeah. It's, you know, per our conversations, Eric, it's, you know, we don't break them out individually, but it is in line with what you would have expected, you know, based on your research, you know, diabetes is significant. Prediabetes is a big one for us. Now we're expanding into new areas like we talked about, when it comes to, you know, 2022 in areas like sleep, hypertension, and others. It's really the major conditions that you would expect. Thanks for that. It sounds like something we'll be following up in the next quarter or two. Justin, when you roll out a new program, and we think about Sharecare's approach to go to market, should we think of these as incremental PMPM, or would you ever have a digital therapeutic that would be covered under medical or pharmacy benefit? In ours, I would look at it incremental PMPM. It could- Okay. It could expand to the models that you're you know. We're looking at that as well. But in the short term, think of incremental PMPM. Gotcha. Last, you mentioned earlier the opportunity outside of enterprise. If this is utilized by a physician, who pays for it in that situation? Are you thinking mostly it would be an at-risk provider who'd be willing to take that on themselves or a consumer, or where does it come from? Yeah. I think we're pursuing kind of all forms of reimbursement. At-risk, you know, direct to consumer, you know. We're looking at all kinds of different models for the therapeutic. All right. Thanks so much. Sure. Thanks so much. Absolutely. Thank you. I'm currently showing no further questions. I turn the call back over to Jeff Arnold for closing remarks. Great, thank you. Well, we appreciate everybody calling in today and learning about our Q3 numbers. We couldn't be more excited about hitting our revenue target and our adjusted EBITDA. We feel like we're gonna end the year really strong and going into next year at nearly a $500 million run rate and look forward to continuing to update you on our progress. Take care. Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.